This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lomaestro, B. M.
Right arrow Articles by Drusano, G. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lomaestro, B. M.
Right arrow Articles by Drusano, G. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2005, p. 461-463, Vol. 49, No. 1
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.1.461-463.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Pharmacodynamic Evaluation of Extending the Administration Time of Meropenem using a Monte Carlo Simulation

Ben M. Lomaestro1* and G. L. Drusano2

Albany Medical Center Hospital,1 Ordway Research Institute, Albany, New York2

Received 27 March 2004/ Returned for modification 7 June 2004/ Accepted 25 September 2004

A Monte Carlo simulation demonstrated that 1 g of meropenem (MEM) every 8 h (q8h) (3-h infusion) has a higher target attainment rate against Pseudomonas aeruginosa than either 500 mg of MEM q8h (3-h infusion) or 0.5 g of imipenem-cilastatin (I-C) q6h (1-h infusion). For other pathogens, 500 mg of MEM q8h was equivalent or superior to I-C.

* Corresponding author. Mailing address: Albany Medical Center Hospital, 43 New Scotland Ave. (MC85), Albany, NY 12208. Phone: (518) 262-3255. Fax: (518) 262-4123. E-mail: lomaesb{at}mail.amc.edu.

Antimicrobial Agents and Chemotherapy, January 2005, p. 461-463, Vol. 49, No. 1
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.1.461-463.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Landersdorfer, C. B., Kirkpatrick, C. M. J., Kinzig-Schippers, M., Bulitta, J. B., Holzgrabe, U., Drusano, G. L., Sorgel, F. (2007). Population Pharmacokinetics at Two Dose Levels and Pharmacodynamic Profiling of Flucloxacillin. Antimicrob. Agents Chemother. 51: 3290-3297 [Abstract] [Full Text]  
  • Sakka, S. G., Glauner, A. K., Bulitta, J. B., Kinzig-Schippers, M., Pfister, W., Drusano, G. L., Sorgel, F. (2007). Population Pharmacokinetics and Pharmacodynamics of Continuous versus Short-Term Infusion of Imipenem-Cilastatin in Critically Ill Patients in a Randomized, Controlled Trial. Antimicrob. Agents Chemother. 51: 3304-3310 [Abstract] [Full Text]  
  • Drusano, G. L. (2007). Pharmacokinetic optimisation of {beta}-lactams for the treatment of ventilator-associated pneumonia. ERR 16: 45-49 [Abstract] [Full Text]  
  • Lodise, T. P. Jr., Pypstra, R., Kahn, J. B., Murthy, B. P., Kimko, H. C., Bush, K., Noel, G. J., Drusano, G. L. (2007). Probability of Target Attainment for Ceftobiprole as Derived from a Population Pharmacokinetic Analysis of 150 Subjects. Antimicrob. Agents Chemother. 51: 2378-2387 [Abstract] [Full Text]  
  • Roos, J. F., Bulitta, J., Lipman, J., Kirkpatrick, C. M. J. (2006). Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. J Antimicrob Chemother 58: 987-993 [Abstract] [Full Text]  
  • Tam, V. H., Kabbara, S., Yeh, R. F., Leary, R. H. (2006). Impact of Sample Size on the Performance of Multiple-Model Pharmacokinetic Simulations. Antimicrob. Agents Chemother. 50: 3950-3952 [Abstract] [Full Text]  
  • Li, C., Kuti, J. L., Nightingale, C. H., Nicolau, D. P. (2006). Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients.. J Clin Pharmacol 46: 1171-1178 [Abstract] [Full Text]  
  • Scheetz, M. H., Hurt, K. M., Noskin, G. A., Oliphant, C. M. (2006). Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens.. Am J Health Syst Pharm 63: 1346-1360 [Abstract] [Full Text]  
  • Tam, V. H., Adams, S., Larocco, M. T., Gerard, L. N., Gentry, L. O., Garey, K. W. (2006). An integrated pharmacoeconomic approach to antimicrobial formulary decision-making. Am J Health Syst Pharm 63: 735-739 [Abstract] [Full Text]  
  • Lorente, L., Lorenzo, L., Martin, M. M, Jimenez, A., Mora, M. L (2006). Meropenem by Continuous Versus Intermittent Infusion in Ventilator-Associated Pneumonia due to Gram-Negative Bacilli. The Annals of Pharmacotherapy 40: 219-223 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»